

1 Neutralising antibodies drive Spike mediated SARS-CoV-2 evasion

2
3 Kemp SA^{1*}, Collier DA^{1,2,3*}, Datir R^{1,2,3}, Gayed S⁴, Jahun A⁵, Hosmillo M⁵, Ferreira IATM^{2,3}, Rees-
4 Spear C¹, Mlcochova P^{2,3}, Ines Ushiro Lumb⁶, David Roberts⁶, Anita Chandra^{2,3}, Temperton N⁷,
5 The CITIID-NIHR BioResource COVID-19 Collaboration⁸, The COVID-19 Genomics UK (COG-UK)
6 Consortium⁹, Sharrocks K⁴, Blane E³, Briggs JAG¹⁰, van Gils MJ¹¹, Smith KGC^{2,3}, Bradley JR^{3,12},
7 Smith C¹⁴, Goldstein RA¹, Goodfellow IG⁵, Smielewska A^{5,13}, Skittrall JP^{4,14,15}, Gouliouris T⁴,
8 Gkrania-Klotsas E⁴, Illingworth CJR^{14,16}, McCoy LE¹, Gupta RK^{2,3,16,17}

9
10 ¹Division of Infection and Immunity, University College London, London, UK.

11 ²Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.

12 ³Department of Medicine, University of Cambridge, Cambridge, UK.

13 ⁴Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust,
14 Cambridge, UK.

15 ⁵Department of Pathology, University of Cambridge, Cambridge

16 ⁶NHS Blood and Transplant, London, UK

17 ⁷Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent, UK

18 ⁸The CITIID-NIHR BioResource COVID-19 Collaboration, see appendix for author list

19 ⁹The COVID-19 Genomics UK (COG-UK) Consortium, <https://www.cogconsortium.uk>. Full list of
20 consortium names and affiliations are in the appendix

21 ¹⁰Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.

22 ¹¹Department of Medical Microbiology, Academic Medical Center, University of Amsterdam,
23 Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands

24 ¹²NIHR Cambridge Clinical Research Facility, Cambridge, UK.

25 ¹³Department of Virology, Cambridge University NHS Hospitals Foundation Trust

26 ¹⁴Department of Applied Mathematics and Theoretical Physics, University of Cambridge, UK

27 ¹⁵Clinical Microbiology and Public Health Laboratory, Addenbrookes' Hospital, Cambridge, UK

28 ¹⁶MRC Biostatistics Unit, University of Cambridge, Cambridge, UK

29 ¹⁷Africa Health Research Institute, Durban, South Africa

30 *equal contribution

31

32 **Address for correspondence:**

33 Ravindra K. Gupta

34 Cambridge Institute for Therapeutic Immunology and Infectious Diseases

35 Jeffrey Cheah Biomedical Centre

36 Puddicombe Way

37 Cambridge CB2 0AW, UK

38 Tel: +44 1223 331491

39 rkg20@cam.ac.uk

40

41 **Key words: SARS-CoV-2; COVID-19; antibody escape, Convalescent plasma; neutralising**
42 **antibodies; mutation; evasion; resistance; immune suppression**

43

44 **Abstract**

45 SARS-CoV-2 Spike protein is critical for virus infection via engagement of ACE2, and amino acid
46 variation in Spike is increasingly appreciated. Given both vaccines and therapeutics are
47 designed around Wuhan-1 Spike, this raises the theoretical possibility of virus escape,
48 particularly in immunocompromised individuals where prolonged viral replication occurs. Here
49 we report fatal SARS-CoV-2 escape from neutralising antibodies in an immune suppressed
50 individual treated with convalescent plasma, generating whole genome ultradeep sequences by
51 both short and long read technologies over 23 time points spanning 101 days. Little
52 evolutionary change was observed in the viral population over the first 65 days despite two
53 courses of remdesivir. However, following convalescent plasma we observed dynamic virus
54 population shifts, with the emergence of a dominant viral strain bearing D796H in S2 and
55 Δ H69/ Δ V70 in the S1 NTD of the Spike protein. As serum neutralisation waned, viruses with the
56 escape genotype diminished in frequency, before returning during a final, unsuccessful course
57 of convalescent plasma. *In vitro*, the Spike escape variant conferred decreased sensitivity to
58 multiple units of convalescent plasma/sera from different recovered patients, whilst

59 maintaining infectivity similar to wild type. These data reveal strong positive selection on SARS-
60 CoV-2 during convalescent plasma therapy and identify the combination of Spike mutations
61 D796H and Δ H69/ Δ V70 as a broad antibody resistance mechanism against commonly occurring
62 antibody responses to SARS-CoV-2.

63

64 **Introduction**

65 SARS-CoV-2 is an RNA betacoronavirus, with closely related viruses identified in pangolins and
66 bats^{1,2}. RNA viruses have inherently higher rates of mutation than DNA viruses such as
67 Herpesviridae³. The capacity for successful adaptation is exemplified by the Spike D614G
68 mutation, that arose in China and rapidly spread worldwide⁴, now accounting for more than
69 90% of infections. The mutation appears to increase infectivity and transmissibility in animal
70 models⁵. Although the SARS-CoV-2 Spike protein is critical for virus infection via engagement of
71 ACE2, substantial Spike amino acid variation is being observed in circulating viruses⁶. Logically,
72 mutations in the receptor binding domain (RBD) of Spike are of particular concern due to the
73 RBD being targeted by neutralising antibodies and therapeutic monoclonal antibodies.

74

75 Deletions in the N-terminal domain (NTD) of Spike S1 are also being increasingly recognised,
76 both within hosts⁷ and across individuals⁸. The evolutionary basis for the emergence of
77 deletions is unclear at present but could be related to escape from immunity or to enhanced
78 fitness/transmission. The most notable deletion in terms of frequency is Δ H69/ Δ V70. This
79 double deletion has been detected in multiple unrelated lineages, including the recent 'Cluster
80 5' mink related strain in the North Jutland region of Denmark (https://files.ssi.dk/Mink-cluster-5-short-report_AFO2). There it was associated with the RBD mutation Y453F in almost 200
82 individuals. Another European cluster in GISAID includes Δ H69/ Δ V70 along with the RBD
83 mutation N439K.

84

85 Although Δ H69/ Δ V70 has been detected multiple times, within-host emergence remains
86 undocumented and the reasons for its selection are unknown. Here we document real time
87 SARS-CoV-2 emergence of Δ H69/ Δ V70 in response to convalescent plasma therapy in an

88 immunocompromised human host, demonstrating broad antibody escape in combination with
89 the S2 mutation D796H.

90

91 **Results**

92 **Clinical case history of SARS-CoV-2 infection in setting of immune-compromised host**

93 Please contact authors for clinical details. Some indices are given in Supplementary table 1 and
94 Supplementary Figure 1 and Supplementary Figure 2). Figure 1 summarises the timing of
95 treatment.

96

97 **Negative SARS-CoV-2 specific antibodies and requirement for convalescent plasma (CP)**

98 Given the history of B cell depletion therapy and hypogammaglobulinemia we measured serum
99 SARS-CoV-2 specific antibodies over the course of the admission. Total serum antibodies to
100 SARS-CoV-2 were tested at days 44 and 50 by S protein immunoassay (Siemens). Results were
101 negative. Three units (200mL each) of convalescent plasma (CP) from three independent
102 donors were obtained from the NHS Blood and Transfusion Service and administered on
103 compassionate use basis. These had been assayed for antibody titres using the validated
104 Euroimmun assay (Supplementary figure 3). Patient serum was subsequently positive for SARS-
105 CoV-2 specific antibodies by S protein immunoassay (Siemens) in the hospital diagnostic
106 laboratory on days 68, 90 and 101.

107

108 **Virus genomic comparative analysis of 23 sequential respiratory samples over 101 days**

109 The majority of samples were respiratory samples from nose and throat or endotracheal
110 aspirates during the period of intubation. Ct values ranged from 16-34 and all 23 respiratory
111 samples were successfully sequenced by standard long read approach as per the ARTIC protocol
112 implemented by COG-UK; of these 20 additionally underwent short-read deep sequencing using
113 the Illumina platform. There was generally good agreement between the methods, though as
114 expected nanopore demonstrated greater error at low variant frequencies (<10%)
115 (Supplementary Figure 4). We detected no evidence of recombination, based on two
116 independent methods.

117
118 Maximum likelihood analysis of patient-derived whole genome consensus sequences
119 demonstrated clustering with other local sequences from the same region (Figure 2A). The
120 infecting strain was assigned to lineage 20B bearing the D614G Spike variant. Environmental
121 sampling showed evidence of virus on surfaces such as telephone and call bell but not in air on
122 days 59, 92 and 101. Sequencing of these surface viruses showed clustering with those derived
123 from the respiratory tract (Figure 2B). All samples were consistent with having arisen from a
124 single viral population. In our phylogenetic analysis, we included sequential sequences from
125 three other local patients identified with persistent viral RNA shedding over a period of 4 weeks
126 or more (Supplementary Table 2). Viruses from these individuals showed very little divergence
127 in comparison to the case patient (Figure 2B) and none showed amino acid changes in Spike
128 over time. We additionally inferred a maximum likelihood phylogeny comparing sequences
129 from these three local individuals and two long term immunosuppressed SARS-CoV-2 ‘shedders’
130 recently reported^{7,9}, (Figure 2B). While the sequences from Avanzato et al showed a pattern of
131 evolution more similar to two of the three other local patients, the case patient showed
132 significant diversification with a mutation rate of 30 per year (Supplementary table 2).

133
134 Further investigation of the sequence data suggested the existence of an underlying structure
135 to the viral population in our patient, with samples collected at days 93 and 95 being rooted
136 within, but significantly divergent from the original population (Figure 2B and 3A). The
137 relationship of the divergent samples to those at earlier time points rules out the possibility of
138 superinfection. The increased divergence of sequences does not necessarily indicate selection;
139 a spatially compartmentalised subset of viruses, smaller in number than the main viral
140 population, would be expected to evolve more quickly than the main population due to the
141 increased effect of genetic drift^{10,11}.

142
143 **Virus population structure changes following convalescent plasma and remdesivir**
144 All samples tested positive by RT-PCR and there was no sustained change in Ct values
145 throughout the 101 days following the first two courses of remdesivir (days 41 and 54), or the

146 first two units of convalescent plasma (days 63 and 65). According to nanopore data, no
147 polymorphisms occurred over the first 60 days at consensus level (Figure 3A). However, short
148 read deep sequence Illumina data revealed minority polymorphisms in the viral population
149 during this period (Figure 3B). For example, T39I in ORF7a reached a majority frequency of 77%
150 on day 44, arising *de novo* and increased in frequency during the first period of the infection
151 (Supplementary Figure 6).

152
153 In contrast to the early period of infection, between days 66 and 82 a dramatic shift in virus
154 population structure was observed, with the near-fixation of D796H in S2 along with
155 Δ H69/ Δ V70 in the S1 N-terminal domain (NTD) at day 82. This was identified in a nose and
156 throat swab sample with high viral load as indicated by Ct of 23 (Figure 4). The deletion was
157 not detected at any point prior to the day 82 sample, even as minority variants by short read
158 deep sequencing.

159
160 On Days 86 and 89, viruses collected were characterised by the Spike mutations Y200H and
161 T240I, with the deletion/mutation pair observed on day 82 having fallen to very low frequency.
162 Sequences collected on these days formed a distinct branch at the bottom of the phylogeny in
163 Figure 4 but were clearly associated with the remainder of the samples, suggesting that they
164 did not result from superinfection (Supplementary Figure 7), and further were not significantly
165 divergent from the bulk of the viral population (Supplementary Figure 5).

166
167 Sequencing of a nose and throat swab sample at day 93 again showed D796H along with
168 Δ H69/ Δ V70 at <10% abundance, along with an increase in a virus population characterised by
169 Spike mutations P330S at the edge of the RBD and W64G in S1 NTD. This new lineage reached
170 near 100% abundance at day 93. Viruses with the P330S variant were detected in two
171 independent samples from different sampling sites, ruling out the possibility of contamination.
172 The divergence of these samples from the remainder of the population, noted above, suggests
173 the possibility of their resulting from the stochastic emergence, in the upper respiratory tract,
174 of a previously unobserved subpopulation of viruses (Supplementary Figure 5).

175

176 Following the third course of remdesivir (day 93) and third CP (day 95), we observed a re-
177 emergence of the D796H + Δ H69/ Δ V70 viral population. The inferred linkage of D796H and
178 Δ H69/ Δ V70 was maintained as evidenced by the highly similar frequencies of the two variants,
179 suggesting that the third unit of CP led to the re-emergence of this viral strain under renewed
180 positive selection. Ct values remained low throughout this period with hyperinflammation,
181 eventually leading to multi-organ failure and death at day 102. The repeated increase in
182 frequency of the novel viral strain during CP therapy strongly supports the hypothesis that the
183 deletion/mutation combination conferred antibody escape properties.

184

185 **Δ H69/ Δ V70 + D796H confers impaired neutralisation by multiple convalescent plasma units**
186 **and sera from recovered COVID-19 patients**

187 Using lentiviral pseudotyping we expressed wild type and Δ H69/ Δ V70 + D796H mutant Spike
188 protein in enveloped virions and compared neutralisation activity of CP against these viruses.
189 This system has been shown to give similar results to replication competent virus^{12,13}. We first
190 tested infection capacity over a single round of infection and found that Δ H69/ Δ V70 + D796H
191 had similar infectivity to wild type (both in a D614G background, Figure 5A, B). The Δ H69/ Δ V70
192 + D796H mutant was partially resistant to the first two CP units (Figure 5C, Table 1A). In
193 addition, patient derived serum from days 64 and 66 (one day either side of CP2 infusion)
194 similarly showed lower potency against the mutant (Figure 5C, Table 1A). The repeated
195 observation of D796H + Δ H69/ Δ V70 emergence and positive selection strengthens the
196 hypothesis that these variants were the key drivers of antibody escape. Experimentally, the
197 D796H + Δ H69/ Δ V70 mutant also demonstrated reduced susceptibility to the CP3 administered
198 on day 95, explaining its re-emergence (Figure 5C, Table 1A).

199

200 Given reduced susceptibility of the mutants to at least two units of CP, and the expansion of
201 sequences bearing Δ H69/ Δ V70, we hypothesised that this represented a broad escape
202 mechanism. We therefore screened antiviral neutralisation activity in sera from five recovered
203 patients against the mutant and wild type viruses (Figure 5D). We observed that the mutant

204 was indeed significantly less susceptible to four of five randomly selected sera, with the fifth
205 showing reduced susceptibility that did not reach statistical significance (Table 1B). Fold change
206 reductions in susceptibility of the mutant were as high as ten-fold compared to wild type (Table
207 1B).

208
209 In order to probe the impact of the D796H and Δ H69/ Δ V70 mutations on potency of
210 monoclonal antibodies (mAbs) targeting Spike, we screened neutralisation activity of a panel of
211 seven neutralizing mAbs across a range of epitope clusters¹³ (Figure 5E). We observed no
212 differences in neutralisation between single mutants and wild type, suggesting that the
213 mechanism of escape was likely outside these epitopes.

214
215 In order to understand the mechanisms that might confer resistance to antibodies we
216 examined a published Spike structure and annotated it our residues of interest (Figure 6). This
217 analysis showed that Δ H69/ Δ V70 is in a disordered, glycosylated loop at the very tip of the
218 NTD, and therefore could alter binding of antibodies. Δ H69/V70 is close to the binding site of
219 the polyclonal antibodies derived from COV57 plasma, indicating the sera tested here may
220 contain similar antibodies^{14,15}. D796H is in an exposed loop in S2 (Figure 6) and appears to be in
221 a region frequently targeted by antibodies¹⁶, despite mutations at position 796 being rare
222 (Supplementary table 4).

223

224 Discussion

225 Here we have documented a repeated evolutionary response by SARS-CoV-2 against antibody
226 therapy during the course of a persistent and eventually fatal infection in an
227 immunocompromised host. The observation of potential selection for specific variants
228 coinciding with the presence of antibodies from convalescent plasma is supported by the
229 experimental finding of reduced susceptibility of these viruses to plasma. Further, we were
230 able to document real-time emergence of a variant Δ H69/ Δ V70 in the NTD of Spike that has
231 been increasing in frequency in Europe. In the case we report that it was not clear that the
232 emergence of the antibody escape variant was the primary reason for treatment failure.

233 However, given that both vaccines and therapeutics are aimed at Spike, our study raises the
234 possibility of virus evasion, particularly in immune suppressed individuals where prolonged viral
235 replication occurs.

236

237 Our observations represent a very rare insight, and only possible due to lack of antibody
238 responses in the individual following administration of the B cell depleting agent rituximab for
239 lymphoma, and an intensive sampling course undertaken due to concerns about persistent
240 shedding and risk of nosocomial transmission. Persistent viral replication and the failure of
241 antiviral therapy allowed us to define the viral response to convalescent plasma, similar to a
242 recent report on asymptomatic long term shedding with four sequences over 105 days⁹,
243 although the reported shifts in genetic composition of the viral population could not be
244 explained phenotypically. Another common finding is the very low neutralisation activity in
245 serum post transfusion of CP with waning as expected. Apart from the difference in the
246 outcome of infection (severe, fatal disease versus asymptomatic disease and clearance),
247 critically important differences in our study include: 1. The intensity of sampling and use of both
248 long and short read sequencing to verify variant calls, thereby providing a unique scientific
249 resource for longitudinal population genetic analysis. 2. The close alignment between the
250 genetic composition of the viral population and CP administration, with an experimentally
251 verified resistant strain emerging, falling to low frequency, and then rising again under CP
252 selection. 3. Real time detection of emergence of a variant, $\Delta H69/\Delta V70$, that is increasing in
253 frequency in Europe, and shown here to affect neutralization by multiple COVID-19 patient
254 derived sera.

255

256 We have noted in our analysis the potential influence of compartmentalised viral replication
257 upon the sequences recovered in upper respiratory tract samples. Both population genetic and
258 small animal studies have shown a lack of reassortment between influenza viruses within a
259 single host during an infection, suggesting that acute respiratory viral infection may be
260 characterised by spatially distinct viral populations^{17,18}. In the analysis of data, it is important to
261 distinguish genetic changes which occur in the primary viral population from apparent changes

262 that arise from the stochastic observation of spatially distinct subpopulations in the host. While
263 the samples we observe on days 93 and 95 of infection are genetically distinct from the others,
264 the remaining samples are consistent with arising from a consistent viral population, supporting
265 the finding of a reversion and subsequent regain of antibody resistance. We note that in a
266 study of SARS-CoV-2, Choi et al reported the detection in postmortem tissue of viral RNA not
267 only in lung tissue, but also in the spleen, liver, and heart⁷. Mixing of virus from different
268 compartments, for example via blood, or movement of secretions from lower to upper
269 respiratory tract, could lead to fluctuations in viral populations at particular sampling sites.
270 Experiments in animal models with sampling of different replication sites could allow a better
271 understanding of SARS-CoV-2 population genetics and enable prediction of escape variants
272 following antibody based therapies.

273
274 This is a single case report and therefore limited conclusions can be drawn about
275 generalisability.

276 In addition to documenting the emergence of SARS-CoV-2 Spike Δ H69/ Δ V70 + D796H *in vivo*,
277 conferring broad reduction in susceptibility to serum/plasma polyclonal, but no effect on a set
278 of predominantly RBD-targeting monoclonal antibodies, these data highlight that infection
279 control measures need to be specifically tailored to the needs of immunocompromised
280 patients. The data also highlight caution in interpretation of CDC guidelines that recommend 20
281 days as the upper limit of infection prevention precautions in immune compromised patients
282 who are afebrile¹⁹. Due to the difficulty with culturing clinical isolates, use of surrogates for
283 infectious virus such as sgRNA are warranted²⁰. However, where detection of ongoing viral
284 evolution is possible, this serves as a clear proxy for the existence of infectious virus. In our case
285 we detected environmental contamination whilst in a single occupancy room and the patient
286 was moved to a negative-pressure high air-change infectious disease isolation room.

287
288 The clinical efficacy of CP has been called into question recently²¹, and our data suggest caution
289 in use of CP in patients with immune suppression of both T cell and B cell arms. In such cases,
290 the antibodies administered have little support from cytotoxic T cells, thereby reducing chances

291 of clearance and raising the potential for escape mutations. Whilst we await further data, CP
292 administered for clinical need in immune suppression, should ideally be undertaken in single
293 occupancy rooms with enhanced infection control precautions, including SARS-CoV-2
294 environmental sampling and real-time sequencing.

295

296

297 **Table 1: Neutralisation activity of convalescent plasma and patient sera taken in between CP**
298 **doses against SARS-CoV-2 viral variants observed in A. patient case. B. five unselected**
299 **patients with recovered COVID-19.** Shown are IC50 dilution titres - the CP or serum reciprocal
300 dilution at which 50% of virus infectivity is lost against wild type (baseline) or D796H + Δ69/70
301 mutant Spike protein expressed on the surface of a lentiviral particle. Fold change is the
302 difference between the two viruses, and values below 1 indicate that the D796H/Δ69/70
303 mutant is less sensitive to the CP or serum. Only the D66 serum sample failed to demonstrate
304 significantly higher resistance of the D796H/Δ69/70 mutant.

305

A.

	IC50 as reciprocal dilution (95% CI)		Fold Change IC50 (95% CI)
	WT	D796H + Δ69/70	
CP1	2480.0 (2104.0 - 2965.0)	924.2 (634.1 - 1316.0)	0.37 (0.24 - 0.56)
D64 serum	163.7 (106.6 - 256.4)	55.6 (29.5 - 100.6)	0.27 (0.12 - 0.77)
CP2	447.1 (305.2 - 670.1)	196 (129.8 - 294.7)	0.47 (0.25 - 0.86)
D66 serum	175.7 (90.7 - 410.4)	85.5 (48.2 - 149.8)	0.82 (0.29 - 1.96)
CP3	280.2 (172.8 - 480.3)	115 (75.0 - 175.5)	0.47 (0.24 - 0.91)

306

307

308

B.

	IC50 as reciprocal dilution (95% CI)		Fold Change IC50 (95% CI)
	WT	D796H + Δ69/70	
Serum 1	994.1 (852.7-1159.0)	755.8 (426.7-1269.0)	0.71 (0.39-1.33)
Serum 2	2107.0 (1680.0-2662.0)	1045.0 (745.9-1387.0)	0.42 (0.27-0.70)

Serum 3	3241.0 (2377.0-4643.0)	347.4 (234.4-505.4)	0.11 (0.07-0.17)
Serum 4	17368.0 (14357.0-22130.0)	2965.0 (2287.0-3767.0)	0.26 (0.20-0.32)
Serum 5	52735.0 (34276.0-93957.0)	3871.0 (3525.0-4252.0)	0.20 (0.17-0.24)

309

310

311 **Ethics**

312 The study was approved by the East of England – Cambridge Central Research Ethics Committee
313 (17/EE/0025). Written informed consent was obtained from both the patient and family.
314 Additional controls with COVID-19 were enrolled to the NIHR BioResource Centre Cambridge
315 under ethics review board (17/EE/0025).

316

317 **Acknowledgements**

318 We are immensely grateful to the patient and his family. We would also like to thank the staff
319 at CUH and the NIHR Cambridge Clinical Research Facility. We would like to thank Dr Ruthiran
320 Kugathasan and Professor Wendy Barclay for helpful discussions and Dr Martin Curran, Dr
321 William Hamilton, and Dr. Dominic Sparkes. We would like to thank Prof Andres Floto and Prof
322 Ferdia Gallagher. We thank Dr James Voss for the kind gift of HeLa cells stably expressing ACE2.
323 COG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research
324 & Innovation (UKRI), the National Institute of Health Research (NIHR) and Genome Research
325 Limited, operating as the Wellcome Sanger Institute. RKG is supported by a Wellcome Trust
326 Senior Fellowship in Clinical Science (WT108082AIA). LEM is supported by a Medical Research
327 Council Career Development Award (MR/R008698/1). SAK is supported by the Bill and Melinda
328 Gates Foundation via PANGEA grant: OPP1175094. DAC is supported by a Wellcome Trust
329 Clinical PhD Research Fellowship. CJRI acknowledges MRC funding (ref: MC_UU_00002/11).
330 This research was supported by the National Institute for Health Research (NIHR) Cambridge
331 Biomedical Research Centre, the Cambridge Clinical Trials Unit (CCTU) and by the UCL
332 Coronavirus Response Fund and made possible through generous donations from UCL's
333 supporters, alumni, and friends (LEM). JAGB is supported by the Medical Research Council

334 (MC_UP_1201/16). IG is a Wellcome Senior Fellow and supported by the Wellcome Trust
335 (207498/Z/17/Z).

336

337 **Author contributions**

338 Conceived study: RKG, SAK, DAC, AS, TG, EGK

339 Designed experiments: RKG, SAK, DAC, LEM, JAGB, EGK, AC, NT, AC, CS

340 Performed experiments: SAK, DAC, LEM, RD, CRS, AJ, IATMF, KS, TG, CJRI, BB, JS, MJvG

341 Interpreted data: RKG, SAK, DAC, PM, LEM, JAGB, PM, SG, KS, TG, JB, KGCS, IG, CJRI, JAGB, IUL,

342 DR, JS, BB, RAG

343

344 **Conflicts of interest**

345 The authors declare no conflicts of interest

346

347 **Methods**

348 *Clinical Sample Collection and Next generation sequencing*

349 Serial samples were collected from the patient periodically from the lower respiratory tract
350 (sputum or endotracheal aspirate), upper respiratory tract (throat and nasal swab), and from
351 stool. Nucleic acid extraction was done from 500µl of sample with a dilution of MS2
352 bacteriophage to act as an internal control, using the easyMAG platform (Biomerieux, Marcy-
353 l'Étoile) according to the manufacturers' instructions. All samples were tested for presence of
354 SARS-CoV-2 with a validated one-step RT q-PCR assay developed in conjunction with the Public
355 Health England Clinical Microbiology ²². Amplification reaction were all performed on a
356 Rotorgene™ PCR instrument. Samples which generated a CT of ≤36 were considered to be
357 positive.

358

359 Sera from recovered patients in the COVIDx study²³ were used for testing of neutralisation
360 activity by SARS-CoV-2 mutants.

361

362 For viral genomic sequencing, total RNA was extracted from samples as described. Samples
363 were sequenced using MinION flow cells version 9.4.1 (Oxford Nanopore Technologies)
364 following the ARTICnetwork V3 protocol (<https://dx.doi.org/10.17504/protocols.io.bbmuik6w>)
365 and BAM files assembled using the ARTICnetwork assembly pipeline
366 (<https://artic.network/ncov-2019/ncov2019-bioinformatics-sop.html>). A representative set of
367 10 sequences were selected and also sequenced using the Illumina MiSeq platform. Amplicons
368 were diluted to 2 ng/μl and 25 μl (50 ng) were used as input for each library preparation
369 reaction. The library preparation used KAPA Hyper Prep kit (Roche) according to manufacturer's
370 instructions. Briefly, amplicons were end-repaired and had A-overhang added; these were then
371 ligated with 15mM of NEXTflex DNA Barcodes (Bio Scientific, Texas, USA). Post-ligation products
372 were cleaned using AMPure beads and eluted in 25 μl. Then, 20 μl were used for library
373 amplification by 5 cycles of PCR. For the negative controls, 1ng was used for ligation-based
374 library preparation. All libraries were assayed using TapeStation (Agilent Technologies,
375 California, USA) to assess fragment size and quantified by QPCR. All libraries were then pooled
376 in equimolar accordingly. Libraries were loaded at 15nM and spiked in 5% PhiX (Illumina,
377 California, USA) and sequenced on one MiSeq 500 cycle using a Miseq Nano v2 with 2x 250
378 paired-end sequencing. A minimum of ten reads were required for a variant call.

379

380 *Bioinformatics Processes*

381 For long-read sequencing, genomes were assembled with reference-based assembly and a
382 curated bioinformatics pipeline with 20x minimum coverage across the whole-genome²⁴. For
383 short-read sequencing, FASTQs were downloaded, poor-quality reads were identified and
384 removed, and both Illumina and PHiX adapters were removed using TrimGalore v0.6.6²⁵.
385 Trimmed paired-end reads were mapped to the National Center for Biotechnology Information
386 SARS-CoV-2 reference sequence MN908947.3 using MiniMap2-2.17 with arguments -ax and sr
387²⁶. BAM files were then sorted and indexed with samtools v1.11 and PCR optical duplicates
388 removed using Picard (<http://broadinstitute.github.io/picard>). Single nucleotide polymorphisms
389 (SNPs) were called using Freebayes v1.3.2²⁷ with a ploidy setting of 1, minimum allele
390 frequency of 0.20 and a minimum depth of five reads. Finally, a consensus sequences of nucleic

391 acids with a minimum whole-genome coverage of at least 20× were generated with BCFtools
392 using a 0% majority threshold.

393

394 *Phylogenetic Analysis*

395 All available full-genome SARS-CoV-2 sequences were downloaded from the GISAID database
396 (<http://gisaid.org/>)²⁸ on 17th September. Duplicate and low-quality sequences (>5% N regions)
397 were removed, leaving a dataset of 138,472 sequences with a length of >29,000bp. All
398 sequences were sorted by name and only sequences sequenced with United Kingdom / England
399 identifiers were retained. From this dataset, a subset of 250 sequences were randomly
400 subsampled using seqtk (<https://github.com/lh3/seqtk>). These 250 sequences were aligned to
401 the 23 patient sequences, as well as three other control patients (persistent long-term shedders
402 from the same hospital) (Supplementary Table 2) and the SARS-CoV-2 reference strain
403 MN908947.3, using MAFFT v7.473 with automatic flavour selection²⁹. Major SARS-CoV-2 clade
404 memberships were assigned to all sequences using the Nextclade server v0.8
405 (<https://clades.nextstrain.org/>).

406

407 Maximum likelihood phylogenetic trees were produced using the above curated dataset using
408 IQ-TREE v2.1.2³⁰. Evolutionary model selection for trees were inferred using ModelFinder³¹
409 and trees were estimated using the GTR+F+I model with 1000 ultrafast bootstrap replicates³².
410 All trees were visualised with Figtree v.1.4.4 (<http://tree.bio.ed.ac.uk/software/figtree/>), rooted
411 on the SARS-CoV-2 reference sequence and nodes arranged in descending order. Nodes with
412 bootstraps values of <50 were collapsed using an in-house script.

413

414 Molecular substitution (clock) rates for the index patient, as well as three long-term shedders
415 and two recently described immunocompromised patients from literature, were estimated
416 using BEAST v2.6.3³⁴ using a HKY substitution model with 4 rate categories drawn from a
417 gamma distribution, a strict clock and a coalescent exponential population tree prior. MCMC
418 was run for 100 million iterations excluding a 15% burn-in. Tracer v1.7.1 was used to analyse
419 the BEAST trace in order extract the clock rate and ensure convergence had occurred.

420

421 *In-depth allele frequency variant calling*

422 The SAMFIRE package³⁵ was used to call allele frequency trajectories from BAM file data. Reads
423 were included in this analysis if they had a median PHRED score of at least 30, trimming the
424 ends of reads to achieve this if necessary. Nucleotides were then filtered to have a PHRED
425 score of at least 30; reads with fewer than 30 such reads were discarded. Distances between
426 sequences, accounting for low-frequency variant information, was also conducted using
427 SAMFIRE. The sequence distance metric, described in an earlier paper¹¹, combines allele
428 frequencies across the whole genome. Where L is the length of the genome, we define $q(t)$ as a
429 $4 \times L$ element vector describing the frequencies of each of the nucleotides A, C, G, and T at each
430 locus in the viral genome sampled at time t. For any given locus i in the genome we calculate
431 the change in allele frequencies between the times t_1 and t_2 via a generalisation of the
432 Hamming distance

433

$$d(q_i(t_1), q_i(t_2)) = \frac{1}{2} \sum_{a \in \{A, C, G, T\}} |q_i^a(t_1) - q_i^a(t_2)|$$

434

435 where the vertical lines indicate the absolute value of the difference. These statistics were then
436 combined across the genome to generate the pairwise sequence distance metric

437

$$D(\mathbf{q}(t_1), \mathbf{q}(t_2)) = \sum_i d(q_i(t_1), q_i(t_2))$$

438

439 The Mathematica software package was used to conduct a regression analysis of pairwise sequence
440 distances against time, leading to an estimate of a mean rate of within-host sequence
441 evolution. In contrast to the phylogenetic analysis, this approach assumed the samples
442 collected on days 93 and 95 to arise via stochastic emission from a spatially separated
443 subpopulation within the host, leading to a lower inferred rate of viral evolution for the bulk of
444 the viral population.

445

446 *Inference of selection*

447 Under the assumption of a large effective population size, a deterministic one-locus model of
448 selection was fitted to genome sequence data describing changes in the frequency of the
449 variant T39I. Where $q(t)$ represents the frequency of a single variant at time t , we used a
450 maximum likelihood method to infer the initial variant frequency at time $t=1$, and the selection
451 coefficient s , for times from the initial time point to the disappearance of the variant from the
452 population. Specifically, where $n(t_i)$ and $N(t_i)$ were the number of observations of the variant
453 and the total read depth at that locus at time t_i , we fitted the model

454

455
$$q(t) = \frac{q(1)e^{st}}{1 - q(1) + q(1)e^{st}}$$

456

457 so as to maximise the binomial likelihood

458

$$L = \sum_i \log \binom{N_i}{n_i} q(t_i)^{n_i} (1 - q(t_i))^{N - n_i}$$

459 A similar calculation was performed to estimate the mean effective selection (incorporating
460 intrinsic selection for the variant plus linkage with other selected alleles) acting upon the
461 variant D796H during the final period of CP therapy. In this case selection was modelled as
462 being time-dependent, kicking in with the administration of therapy. We fitted the model:

463

$$q(t) = \begin{cases} q & \text{if } t < \tau \\ \frac{qe^{s(t-\tau)}}{1 - q + qe^{s(t-\tau)}} & \text{if } t \geq \tau \end{cases}$$

464

465 to the data, setting $\tau = 95$.

466

467 *Recombination Detection*

468 All sequences were tested for potential recombination, as this would impact on evolutionary
469 estimates. Potential recombination events were explored with nine algorithms (RDP, MaxChi,
470 SisScan, GeneConv, Bootscan, PhyIPro, Chimera, LARD and 3SEQ), implemented in RDP5 with

471 default settings³⁶. To corroborate any findings, ClonalFrameML v1.12³⁷ was also used to infer
472 recombination breakpoints. Neither programs indicated evidence of recombination in our data.
473

474 *Structural Viewing*

475 The Pymol Molecular Graphics System v2.4.0 ([https://github.com/schrodinger/pymol-open-](https://github.com/schrodinger/pymol-open-source/releases)
476 [source/releases](https://github.com/schrodinger/pymol-open-source/releases)) was used to map the location of the four spike mutations of interested onto a
477 SARS-CoV-2 spike structure visualised by Wrobel et al (PDB: 6ZGE)³⁸.

478

479 *Generation of Spike mutants*

480 Amino acid substitutions were introduced into the D614G pCDNA_SARS-CoV-2_Spike plasmid
481 as previously described³⁹ using the QuikChange Lightning Site-Directed Mutagenesis kit,
482 following the manufacturer's instructions (Agilent Technologies, Inc., Santa Clara, CA).

483

484 *Pseudotype virus preparation*

485 Viral vectors were prepared by transfection of 293T cells by using Fugene HD transfection
486 reagent (Promega). 293T cells were transfected with a mixture of 11ul of Fugene HD, 1µg of
487 pCDNAΔ19Spike-HA, 1ug of p8.91 HIV-1 gag-pol expression vector^{40,41}, and 1.5µg of pCSFLW
488 (expressing the firefly luciferase reporter gene with the HIV-1 packaging signal). Viral
489 supernatant was collected at 48 and 72h after transfection, filtered through 0.45um filter and
490 stored at -80°C. The 50% tissue culture infectious dose (TCID₅₀) of SARS-CoV-2 pseudovirus
491 was determined using Steady-Glo Luciferase assay system (Promega).

492

493 *Serum/plasma pseudotype neutralization assay*

494 Spike pseudotype assays have been shown to have similar characteristics as neutralisation
495 testing using fully infectious wild type SARS-CoV-2¹². Virus neutralisation assays were performed
496 on 293T cell transiently transfected with ACE2 and TMPRSS2 using SARS-CoV-2 Spike
497 pseudotyped virus expressing luciferase⁴². Pseudotyped virus was incubated with serial dilution
498 of heat inactivated human serum samples or convalescent plasma in duplicate for 1h at 37°C.
499 Virus and cell only controls were also included. Then, freshly trypsinized 293T ACE2/TMPRSS2

500 expressing cells were added to each well. Following 48h incubation in a 5% CO₂ environment at
501 37°C, the luminescence was measured using Steady-Glo Luciferase assay system (Promega).

502

503 *mAb pseudotype neutralisation assay*

504 Virus neutralisation assays were performed on HeLa cells stably expressing ACE2 and using
505 SARS-CoV-2 Spike pseudotyped virus expressing luciferase as previously described⁴³.

506 Pseudotyped virus was incubated with serial dilution of purified mAbs¹³ in duplicate for 1h at
507 37°C. Then, freshly trypsinized HeLa ACE2- expressing cells were added to each well. Following
508 48h incubation in a 5% CO₂ environment at 37°C, the luminescence was measured using Bright-
509 Glo Luciferase assay system (Promega) and neutralization calculated relative to virus only
510 controls. IC50 values were calculated in GraphPad Prism.

511

512 **Data Availability**

513 Long-read sequencing data that support the findings of this study have been deposited in the
514 NCBI SRA database with the accession codes SAMN16976824 - SAMN16976846 under
515 BioProject PRJNA682013 (<https://www.ncbi.nlm.nih.gov/bioproject/PRJNA682013>). Short reads
516 and data used to construct figures were deposited at [https://github.com/Steven-](https://github.com/Steven-Kemp/sequence_files)
517 [Kemp/sequence files](https://github.com/Steven-Kemp/sequence_files).

518

519 **References**

- 520 1 Zhang, T., Wu, Q. & Zhang, Z. Probable pangolin origin of SARS-CoV-2 associated with the
521 COVID-19 outbreak. *Current Biology* (2020).
- 522 2 Xiao, K. *et al.* Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins. *Nature* **583**,
523 286-289, doi:10.1038/s41586-020-2313-x (2020).
- 524 3 Sanjuán, R. & Domingo-Calap, P. Mechanisms of viral mutation. *Cell Mol Life Sci* **73**, 4433-4448,
525 doi:10.1007/s00018-016-2299-6 (2016).
- 526 4 Korber, B. *et al.* Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases
527 Infectivity of the COVID-19 Virus. *Cell*, doi:10.1016/j.cell.2020.06.043 (2020).
- 528 5 Yurkovetskiy, L. *et al.* Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein
529 Variant. *Cell* **183**, 739-751 e738, doi:10.1016/j.cell.2020.09.032 (2020).


- 530 6 Korber, B. *et al.* Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity
531 of the COVID-19 virus. *Cell* **182**, 812-827. e819 (2020).
- 532 7 Choi, B. *et al.* Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. *N Engl*
533 *J Med*, doi:10.1056/NEJMc2031364 (2020).
- 534 8 McCarthy, K. R. *et al.* Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody
535 escape. *bioRxiv*, 2020.2011.2019.389916, doi:10.1101/2020.11.19.389916 (2020).
- 536 9 Avanzato, V. A. *et al.* Case Study: Prolonged infectious SARS-CoV-2 shedding from an
537 asymptomatic immunocompromised cancer patient. *Cell* (2020).
- 538 10 Wright, S. Size of population and breeding structure in relation to evolution. *Science*, 430-431
539 (1938).
- 540 11 Lumby, C. K., Zhao, L., Breuer, J. & Illingworth, C. J. A large effective population size for
541 established within-host influenza virus infection. *Elife* **9**, doi:10.7554/eLife.56915 (2020).
- 542 12 Schmidt, F. *et al.* Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and
543 chimeric viruses. 2020.2006.2008.140871, doi:10.1101/2020.06.08.140871 %J bioRxiv (2020).
- 544 13 Brouwer, P. J. M. *et al.* Potent neutralizing antibodies from COVID-19 patients define multiple
545 targets of vulnerability. *Science* **369**, 643-650, doi:10.1126/science.abc5902 (2020).
- 546 14 Robbiani, D. F. *et al.* Convergent antibody responses to SARS-CoV-2 in convalescent individuals.
547 *Nature* **584**, 437-442, doi:10.1038/s41586-020-2456-9 (2020).
- 548 15 Barnes, C. O. *et al.* Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common
549 Epitopes and Recurrent Features of Antibodies. *Cell* **182**, 828-842 e816,
550 doi:10.1016/j.cell.2020.06.025 (2020).
- 551 16 Shrock, E. *et al.* Viral epitope profiling of COVID-19 patients reveals cross-reactivity and
552 correlates of severity. *Science*, doi:10.1126/science.abd4250 (2020).
- 553 17 Sobel Leonard, A. *et al.* The effective rate of influenza reassortment is limited during human
554 infection. *PLoS pathogens* **13**, e1006203, doi:10.1371/journal.ppat.1006203 (2017).
- 555 18 Richard, M., Herfst, S., Tao, H., Jacobs, N. T. & Lowen, A. C. Influenza A Virus Reassortment Is
556 Limited by Anatomical Compartmentalization following Coinfection via Distinct Routes. *Journal*
557 *of virology* **92**, doi:10.1128/JVI.02063-17 (2018).
- 558 19 CDC. *Discontinuation of Transmission-Based Precautions and Disposition of Patients with COVID-*
559 *19 in Healthcare Settings (Interim Guidance)*, <<https://www.cdc.gov/coronavirus/2019-ncov/hcp/disposition-hospitalized-patients.html>> (2020).
- 560

- 561 20 Boshier, F. A. T. *et al.* Remdesivir induced viral RNA and subgenomic RNA suppression, and
562 evolution of viral variants in SARS-CoV-2 infected patients. *medRxiv*, 2020.2011.2018.20230599,
563 doi:10.1101/2020.11.18.20230599 (2020).
- 564 21 Simonovich, V. A. *et al.* A Randomized Trial of Convalescent Plasma in Covid-19 Severe
565 Pneumonia. *N Engl J Med*, doi:10.1056/NEJMoa2031304 (2020).
- 566 22 Meredith, L. W. *et al.* Rapid implementation of SARS-CoV-2 sequencing to investigate cases of
567 health-care associated COVID-19: a prospective genomic surveillance study. *The Lancet*
568 *Infectious Diseases* **20**, 1263-1272, doi:10.1016/S1473-3099(20)30562-4 (2020).
- 569 23 Collier, D. A. *et al.* Point of Care Nucleic Acid Testing for SARS-CoV-2 in Hospitalized Patients: A
570 Clinical Validation Trial and Implementation Study. *Cell Rep Med*, 100062,
571 doi:10.1016/j.xcrm.2020.100062 (2020).
- 572 24 Loman, N., Rowe, W. & Rambaut, A. (v1, 2020).
- 573 25 Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads.
574 *EMBnet. journal* **17**, 10-12 (2011).
- 575 26 Li, H. Minimap2: pairwise alignment for nucleotide sequences. *Bioinformatics (Oxford, England)*
576 **34**, 3094-3100, doi:10.1093/bioinformatics/bty191 (2018).
- 577 27 Garrison, E. & Marth, G. Haplotype-based variant detection from short-read sequencing. *arXiv*
578 *preprint arXiv:1207.3907* (2012).
- 579 28 Shu, Y. & McCauley, J. GISAI: Global initiative on sharing all influenza data - from vision to
580 reality. *Euro surveillance : bulletin European sur les maladies transmissibles = European*
581 *communicable disease bulletin* **22**, 30494, doi:10.2807/1560-7917.ES.2017.22.13.30494 (2017).
- 582 29 Katoh, K. & Standley, D. M. MAFFT Multiple Sequence Alignment Software Version 7:
583 Improvements in Performance and Usability. *Molecular Biology and Evolution* **30**, 772-780,
584 doi:10.1093/molbev/mst010 (2013).
- 585 30 Minh, B. Q. *et al.* IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in
586 the Genomic Era. *Molecular Biology and Evolution* **37**, 1530-1534, doi:10.1093/molbev/msaa015
587 (2020).
- 588 31 Kalyaanamoorthy, S., Minh, B. Q., Wong, T. K. F., von Haeseler, A. & Jermiin, L. S. ModelFinder:
589 fast model selection for accurate phylogenetic estimates. *Nature Methods* **14**, 587-589,
590 doi:10.1038/nmeth.4285 (2017).
- 591 32 Minh, B. Q., Nguyen, M. A. T. & von Haeseler, A. Ultrafast Approximation for Phylogenetic
592 Bootstrap. *Molecular Biology and Evolution* **30**, 1188-1195, doi:10.1093/molbev/mst024 (2013).

- 593 33 Sagulenko, P., Puller, V. & Neher, R. A. TreeTime: Maximum-likelihood phylodynamic analysis.
594 *Virus evolution* **4**, vex042-vex042, doi:10.1093/ve/vex042 (2018).
- 595 34 Bouckaert, R. *et al.* BEAST 2: a software platform for Bayesian evolutionary analysis. *PLoS*
596 *Comput Biol* **10**, e1003537 (2014).
- 597 35 Illingworth, C. J. SAMFIRE: multi-locus variant calling for time-resolved sequence data.
598 *Bioinformatics* **32**, 2208-2209, doi:10.1093/bioinformatics/btw205 (2016).
- 599 36 Martin, D. P., Murrell, B., Golden, M., Khoosal, A. & Muhire, B. RDP4: Detection and analysis of
600 recombination patterns in virus genomes. *Virus evolution* **1** (2015).
- 601 37 Didelot, X. & Wilson, D. J. ClonalFrameML: efficient inference of recombination in whole
602 bacterial genomes. *PLoS Comput Biol* **11**, e1004041 (2015).
- 603 38 Wrobel, A. G. *et al.* SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus
604 evolution and furin-cleavage effects. *Nature Structural & Molecular Biology* **27**, 763-767,
605 doi:10.1038/s41594-020-0468-7 (2020).
- 606 39 Gregson, J. *et al.* HIV-1 viral load is elevated in individuals with reverse transcriptase mutation
607 M184V/I during virological failure of first line antiretroviral therapy and is associated with
608 compensatory mutation L74I. *The Journal of infectious diseases*, doi:10.1093/infdis/jiz631
609 (2019).
- 610 40 Naldini, L., Blomer, U., Gage, F. H., Trono, D. & Verma, I. M. Efficient transfer, integration, and
611 sustained long-term expression of the transgene in adult rat brains injected with a lentiviral
612 vector. *Proceedings of the National Academy of Sciences of the United States of America* **93**,
613 11382-11388 (1996).
- 614 41 Gupta, R. K. *et al.* Full-length HIV-1 Gag determines protease inhibitor susceptibility within in
615 vitro assays. *Aids* **24**, 1651-1655, doi:10.1097/QAD.0b013e3283398216 (2010).
- 616 42 Mlcochova, P. *et al.* Combined point of care nucleic acid and antibody testing for SARS-CoV-2
617 following emergence of D614G Spike Variant. *Cell Rep Med*, 100099,
618 doi:10.1016/j.xcrm.2020.100099 (2020).
- 619 43 Seow, J. *et al.* Longitudinal observation and decline of neutralizing antibody responses in the
620 three months following SARS-CoV-2 infection in humans. *Nat Microbiol* **5**, 1598-1607,
621 doi:10.1038/s41564-020-00813-8 (2020).
- 622

Figure 1

A



B




Figure 1. Analysis of 23 Patient derived whole SARS-CoV-2 genome sequences in context of national sequences and other cases of chronic SARS-CoV-2 shedding. A. Circularised maximum-likelihood phylogenetic tree rooted on the Wuhan-Hu-1 reference sequence, showing a subset of 250 local SARS-CoV-2 genomes from GISAID. This diagram highlights significant diversity of the case patient (green) compared to three other local patients with prolonged shedding (blue, red and purple sequences). All SARS-CoV-2 genomes were downloaded from the GISAID database and a random subset of 250 local sequences selected. B. Close-view maximum-likelihood phylogenetic tree indicating the diversity of the case patient and three other long-term shedders from the local area (red, blue and purple), compared to recently published sequences from Choi et al (orange) and Avanzato et al (gold). Control patients generally showed limited diversity temporally, though the Choi et al sequences were found to be even more divergent than the case patient. Environmental samples are indicated. 1000 ultrafast bootstraps were performed and support at nodes is indicated.

A C T G del

Figure 2






Figure 2. Virus genetics and population structure in chronic SARS-CoV-2 infection. **A.** Highlighter plot indicating nucleotide changes at consensus level in sequential respiratory samples compared to the consensus sequence at first diagnosis of COVID-19. Each row indicates the timepoint the sample was collected (number of days from first positive SARS-CoV-2 RT-PCR). Black dashed lines indicate the RNA-dependent RNA polymerase (RdRp) and Spike regions of the genome. Of particular interest, at consensus level, there were no nucleotide substitutions on days 1-57, despite the patient receiving two courses of remdesivir. The first major changes in the spike genome occurred on day 82, following convalescent plasma given on days 63 and 65. The double amino acid deletion in S1, Δ H69/V70 is indicated by black lines. All samples are nose and throat swabs unless indicated with ETA (endotracheal aspirate). **B.** Whole genome amino acid variant trajectories based on Illumina short read ultra deep sequencing at 1000x coverage. All variants which reached a frequency of at least 10% in at least two samples were plotted. Black dashed line represents Δ 69/70. CP, convalescent plasma; RDV, Remdesivir.

Figure 3

A



B




Figure 3. Longitudinal variant frequencies and phylogenetic relationships for virus populations bearing six Spike (S) mutations **A.** At baseline, all four S variants (Illumina sequencing) were absent (<1% and <20 reads). Approximately two weeks after receiving two units of convalescent plasma (CP), viral populations carrying Δ H69/V70 and D796H mutants rose to frequencies >90% but decreased significantly four days later. This population was replaced by a population bearing Y200H and T240I, detected in two samples over a period of six days. These viral populations were then replaced by virus carrying W64G and P330S mutations in Spike, which both reached near fixation at day 93. Following a 3rd course of remdesivir and an additional unit of convalescent plasma, the Δ H69/V70 and D796H virus population re-emerged to become the dominant viral strain reaching variant frequencies of >90%. Pairs of mutations arose and disappeared simultaneously indicating linkage on the same viral haplotype. **B.** Maximum likelihood phylogenetic tree of the case patient with day of sampling indicated. Spike mutations defining each of the clades are shown ancestrally on the branches on which they arose. Number at node denotes support by ultrafast bootstrapping consisting of 1000 replicates.

Figure 4




Figure 4: Spike mutant D796H + ΔH69/V70 has infectivity comparable to wild type but is less sensitive to multiple units of convalescent plasma (CP) and sera from recovered individuals. A. Reverse transcriptase activity of virus supernatants containing lentivirus pseudotyped with SARS-CoV-2 Spike protein (WT versus mutant) **B.** Single round Infectivity of luciferase expressing lentivirus pseudotyped with SARS-CoV-2 Spike protein (WT versus mutant) on 293T cells co-transfected with ACE2 and TMPRSS2 plasmids. **C.** Patient serum (taken at indicated Day (D)) and convalescent plasma (CP units 1-3) neutralization potency against Spike mutant D796H + ΔH69/V70 measured using lentivirus pseudotyped with SARS-CoV-2 Spike protein (WT versus mutant). Indicated is serum dilution required to inhibit 50% of virus infection. **D.** Neutralization potency of sera from 5 unselected convalescent patients (with previous confirmed SARS-CoV-2 infection) against WT versus mutant virus as in panel C. **E** Neutralization potency of a panel of monoclonal antibodies against lentivirus pseudotyped with SARS-CoV-2 Spike protein (WT Wuhan versus single mutants D614G, D796H, ΔH69/V70). Data are representative of at least two independent experiments * p<0.05

Figure 5




Figure 5. Location of Spike mutations Δ H69/Y70 in S1 and D796H in S2. Amino acid residues H69 and Y70 deleted in the N-terminal domain (red) and D796H in subunit 2 (orange) are highlighted on a SARS-CoV-2 spike trimer (PDB: 6ZGE Wrobel et al., 2020). Each of the three protomers making up the Spike homotrimer are coloured separately in shades of grey (centre). Close-ups of Δ H69/Y70 (above) and D796H (below) are shown in cartoon, stick representation. Both mutations are in exposed loops.